Skip to main content
Have a personal or library account? Click to login
A Decade of Nasopharyngeal Carcinoma: Survival, Failure Patterns, and Prognostic Factors- A Single Institutional Experience Cover

A Decade of Nasopharyngeal Carcinoma: Survival, Failure Patterns, and Prognostic Factors- A Single Institutional Experience

Open Access
|Nov 2026
Read online

Figures & tables

Table 1.

Clinicopathological characteristics and treatment outcomes according to survival status in Nasopharyngeal Carcinoma.

CharacteristicsTotal n=431Alive 364(84.5%)Dead 67(15.5%)p-value
Patient Characteristics
Age (Median)@48 (16–94)48 (16–94)45 (19–71)0.542
  Age Groups
  <40 Years148 (34.3)126 (34.6)22 (32.8)0.889
  ≥40 Years283 (65.7)238 (65.4)45 (67.2)
Gender
  Female139 (32.3)119 (32.7)20 (29.9)0.776
  Male292 (67.7)245 (67.3)47 (70.1)
Stage Group
  Stage I4 (0.9)3 (0.8)1 (1.5)0.107
  Stage II35 (8.1)33 (9.1)2 (3.0)
  Stage III101 (23.4)90 (24.7)11 (16.4)
  Stage IV291 (67.5)238 (65.4)53 (79.1)
Nodal Stage
  N040 (9.3)32 (8.8)8 (11.9)0.195
  N171 (16.5)61 (16.8)10 (14.9)
  N2179 (41.5)158 (43.4)21 (31.3)
  N3141 (32.7)113 (31.0)28 (41.8)
Treatment Variables
Planning Technique
  3DCRT/Conventional143 (33.2)118 (32.4)25 (37.3)0.481
  IMRT/Rapid Arc288 (66.8)246 (67.6)42 (62.7)
Radiotherapy Dose
  ≥65 Gy412 (95.6)351 (96.4)61 (91.0)0.095
  <65 Gy19 (4.4)13 (3.6)6 (9.0)
Chemotherapy Setting
  Induction412 (95.6)349 (95.9)63 (94.0)0.191
  Adjuvant8 (1.9)5 (1.4)3 (4.5)
  No chemotherapy11 (2.6)10 (2.7)1 (1.5)
Concurrent Chemotherapy with RT
  Yes391 (90.7)336 (92.3)55 (82.1)0.019*
  No40 (9.3)28 (7.7)12 (17.9)
Outcomes
Treatment Response
  Complete307 (71.2)269 (73.9)38 (56.7)<0.008**
  Other (partial/stable/progression)124 (28.8)95 (26.1)29 (43.3)
Recurrence
  Yes143 (33.2)90 (24.7)53 (79.1)<0.001**
  No288 (66.8)274 (75.3)14 (20.9)
Site of Recurrence (n=143)
  Local70 (49.0)45 (50.0)25 (47.2)0.863
  Distant73 (51.0)45 (50.0)28 (52.8)
Palliative Chemotherapy (n=184)
  Yes80 (43.5)49 (36.6)31 (62.0)0.003**
  No104 (56.5)85 (63.4)19 (38.0)
Recurrence Free Survival
  > 5 years125 (29)122 (33.5)03 (4)<0.001**
  ≤ 5 years306 (71)242 (66.5)64 (96)
Survival
  > 5 years184 (42.7)175 (48)09 (13)<0.001**
  ≤ 5 years247 (57.3)189 (52)58 (87)

Chi square or Fishers’ Exact Test is applied for all the categorical variables as appropriate. Column wise percentages are presented in the table.

3DCRT = Three-Dimensional Conformal Radiotherapy.

IMRT = Intensity-Modulated Radiotherapy.

* Statistically significant.

** Statistically highly significant.

@ Mann Whitney Test.

Table 2.

Univariate and Multivariate Analysis of Prognostic Factors for Overall Survival in Nasopharyngeal Carcinoma.

FactorsUnivariateMultivariate
HR [95% CI]P-valueHR [95% CI]P-value
GenderFemaleRef-1.32(0.761–2.292)0.324
Male1.176(0.695–1.989)0.545
Age (Years)Age <40Ref-1.206(0.698–2.084)0.503
Age ≥ 401.116(0.668–1.861)0.676
Chemotherapy concurrentYes0.495(0.258–0.948)0.034*0.411(0.189–0.891)0.024*
NoRef-
Chemotherapy settingInductionRef-1
Adjuvant2.364 [0.740–7.556]0.1471.196(0.323–4.431)0.789
No Chemo0.501(0.069–3.169)0.4930.329(0.035–3.104)0.331
StageI, IIRef-6.984(1.541–31.657)0.021*
III, IV4.627 [1.129–18.961]0.033*
RT Dose<65 Gy1.440(0.570–3.635)0.4402.134(0.744–6.118)0.158
≥ 65 GyRef-
Planning Technique3D Conformal + ConventionalRef---
IMRT0.885(0.121–6.482)0.9050.786(0.105–5.870)0.815
VMAT0.330(0.041–2.642)0.2960.316(0.038–6.118)0.284

3DCRT = Three-Dimensional Conformal Radiotherapy.

IMRT = Intensity-Modulated Radiotherapy, Gy=Gray.

* Statistically significant.

** Statistically highly significant.

Table 3.

Univariate and Multivariate Analysis of Prognostic Factors for Recurrence-free Survival in Nasopharyngeal Carcinoma

FactorsUnivariateMultivariate
HR [95% CI]P-valueHR [95% CI]P-value
GenderFemaleRef-1.175(0.812–1.701)0.392
Male1.172(0.821–1.672)0.382
Age (Years)Age <40Ref-1.554(1.065–2.267)0.022*
Age ≥ 401.346(0.943–1.922)0.102
Chemotherapy concurrentYes0.870(0.492–1.540)0.6630.553(0.296–1.034)0.063
NoRef-
ChemotherapyInductionRef---
Adjuvant0.383(0.054–2.740)0.3390.206(0.027–1.565)0.127
No Chemo0.209(0.029–1.496)0.1190.104(0.013–0.831)0.033*
StageI, IIRef2.047(1.027–4.081)0.42
III, IV1.905(0.970–3.744)0.061
RT Dose<65 Gy2.713(1.464–5.027)0.002**4.372(2.288–8.352)<0.001**
≥ 65 GyRef
Planning Technique3D Conformal +ConventionalRef---
IMRT0.522(0.163–1.665)0.2720.472(0.147–1.522)0.209
VMAT0.322(0.097–1.067)0.0640.279(0.083–0.935)0.039*

3DCRT = Three-Dimensional Conformal Radiotherapy.

IMRT = Intensity-Modulated Radiotherapy, Gy=Gray.

* Statistically significant.

** Statistically highly significant.

Table 5.

Restricted Mean Survival Time and Median Follow-Up in Nasopharyngeal Carcinoma.

StatisticsOverall (months)Recurrence Free (Months)
Restricted Mean Survival Time176.43±11.51 (153.88–198.98)91.08±3.40 (84.42–97.74)
Median1 Follow-up61.0 (57.55–64.45)59.00 (56.56–61.44)

1 Calculated by using reverse Kaplan Meier Method.

Table 4.

Long-Term Overall and Recurrence-Free Survival Rates in Nasopharyngeal Carcinoma.

Time PointSurvival Rate (%) (95% C.I)
OverallRecurrence Free
5- Year83.3 (79.3–87.4)63.2 (58.4–68.5)
7-Year81.3 (76.9–86.0)55.6 (49.2–62.7)
10-Year71.2 (61.7–82.2)55.6 (49.2–62.7)
Figure 1.

Kaplan-Meier curve of overall survival according to clinical stage in nasopharyngeal carcinoma.

Figure 2.

Kaplan-Meier curve of recurrence-free survival according to clinical stage in nasopharyngeal carcinoma.

Language: English
Page range: 153 - 161
Published on: Nov 11, 2026
Published by: Shakuat Khanum Memorial Cancer Hospital and Research Centre
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2026 Anusha Haider, Syed Mohsin Raza, Sana Liaquat, Ahmed Ammar, Hamza Shakeel, Afshan Khanum, Asma Rashid, Zaheer Abbas, Muneeb Uddin Karim, published by Shakuat Khanum Memorial Cancer Hospital and Research Centre
This work is licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License.